Oncology / HR+/HER2- Breast Cancer

Indication

HR+/HER2- Metastatic Breast Cancer

Assets addressing this indication.

Total attributable cost

$22.7B

$214,664/patient

Drug spend

$2.4B

$22,727/patient

How this is calculated ↗

11% of total cost is drugs

Metastatic (stage IV), de novo and recurrent · US